
A new era in cancer treatment is dawning. And with its unique capabilities, Champions Biotechnology is leading the way. Empowering you and your physician as never before.
Founded by some of the world's most renowned specialists in the field of cancer diagnosis, treatment and research, Champions is expanding the frontiers of cancer therapy by providing access to unparalleled personalized treatment options for physicians and their patients. Champions provides you and your physician with real time access to cutting-edge medicine, including respected insight into promising cancer treatments, genetic tests, novel therapeutics and landmark research.
What are the advantages of Champions' personalized cancer treatment? Champions offers a more precise approach to treatment – one that, in partnership with your physician, can optimize the treatment plan's potential for success and maximizes your most precious resource - time. Simply put, this means if therapeutic success is not achieved initially, Champions' technology may provide you more time for new drugs and treatments to develop for the benefit of you and your family. And, sometimes, more time can make all the difference.
To accelerate the pace of science in the fight against cancer.
Dr. David Sidransky co-founded Champions based upon his passionate commitment to win the fight against cancer. His vision is expressed by providing cancer patients and their physicians with timely access to evidence-based breakthroughs in science and medicine. To accomplish this mission, the Champions Personalized Oncology Services team is comprised of professionals whose lives have been touched by cancer and who are also passionately dedicated to finding curative treatments for this deadly disease.
Champions Biotechnology, Inc., evolved twenty-three years ago from a small merger and acquisition public company founded by James Martell under the name "International Group, Inc."
The serendipitous opportunity to create a public biotechnology company arose from tragic circumstances involving Mr. Martell's very close friend. Four and half years ago, his friend was diagnosed with a rare, very aggressive and deadly cancer. Mr. Martell became involved helping and assisting him as a point person and patient advocate involved in all the aspects of his care. As a result of a chance event, while searching for doctors, he met Dr. David Sidransky, who assumed control of his friend's clinical care and the research efforts on his friend's behalf.
Dr. Sidransky and Mr. Martell worked closely and collaborated in developing treatment strategies for his friend's cancer. Mr. Martell strongly believes that Dr. Sidransky's world class expertise and out of the box thinking greatly extended his friend's life. After Mr. Martell's friend passed away, their working relationship continued in the pursuit and expansion of the novel programs that had been established through research efforts and grants initiated by his Mr. Martell's friend. Since that time, Dr. Sidransky and Mr. Martell desired to form a biotechnology company that could advance the current state of cancer treatment, and prolong and improve the lives of cancer patients. In January 2007, they decided to focus on building a biotechnology company from the “ground up” as Champions' new business model; Champions Biotechnology, Inc. became the vehicle to achieve their collective vision.
The Company's shares trade on the OTC (Over-The-Counter) Bulletin Board. The trading symbol is CSBR. All of the Company's SEC filings as well as information on its growing business and recent news can be found on the Company's Web site: ChampionsBiotechnology.com